In order to evaluate the pipeline, we chose ADAM15 because of its known increased expression in breast and lung cancers (Schützet al., 2005) and well characterized alternative splicing events generating distinct transcript isoforms (Kleinoet al., 2007). Here, ADAM15 is linked to lung carcinoma.